Transaction #24421 · Form 4 · 0001193125-25-331299
4D Molecular Therapeutics, Inc. · Exercise / conversion · Common Stock
4D Molecular Therapeutics, Inc. · Transacted December 20, 2025 · Filed December 23, 2025
What does this filing report?
An SEC Form 4 filing for 4D Molecular Therapeutics, Inc. records an exercise / conversion involving Common Stock on December 20, 2025. The reported quantity was 866. The filing date is December 23, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company CIK
- 0001650648
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 866
- Reported price
- Not reported · See footnotes
- Reference value
- Not reported
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 46,528
- Ownership description
- Not reported
- SEC acceptance time
- Dec 23, 2025, 9:05 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Gupta Ashoo ↗
VP, Finance and Controller
CIK 0002091461
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Restricted Stock Units convert into common stock on a one-for-one basis.
- F2
- The transaction represents an automatic sale to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
- F3
- The shares underlying the restricted stock unit award shall vest as to 25% of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company.
- F4
- The shares underlying the restricted stock unit award shall vest as to 1/16th of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.